Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations

Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.03022 Journal of Clinical Oncology - published online before print January 28, 2020 PMID: Therapy for Stage IV Non (...) –Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update , MD 1 x Nasser H. Hanna ; , MD 2 x Bryan J. Schneider ; , MSPH 3 x Sarah Temin ; , MD 4 x Sherman Baker Jr ; , MD 5 x Julie Brahmer ; , MD, PhD 6 x Peter M. Ellis ; , MD, MBA 7 , 8 x Laurie E. Gaspar ; , MD 9 x Rami Y. Haddad ; , MD 10 x Paul J. Hesketh ; , MD 11 x Dharamvir Jain ; , MD 12 x Ishmael Jaiyesimi ; , MD 13 x David H. Johnson ; , MD 14 x Natasha B. Leighl ; , MD 15 x Tanyanika Phillips ; , MD

2020 American Society of Clinical Oncology Guidelines

2. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations ASCO special articles TherapyforStageIVNon–Small-CellLungCancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Nasser H. Hanna,MD 1 ; Bryan J. Schneider,MD 2 ; Sarah Temin, MSPH 3 ; Sherman Baker Jr, MD 4 ; Julie Brahmer,MD 5 ; Peter M. Ellis, MD, PhD 6 ; Laurie E. Gaspar, MD, MBA 7,8 ; Rami Y. Haddad,MD 9 ; Paul J. Hesketh,MD 10 ; Dharamvir Jain,MD 11 ; Ishmael Jaiyesimi,MD 12 ; David H. Johnson,MD (...) 13 ; Natasha B. Leighl,MD 14 ; Tanyanika Phillips,MD 15 ; Gregory J. Riely, MD, PhD 16 ; Andrew G. Robinson,MD 17 ; Rafael Rosell,MD 18 ; Joan H. Schiller,MD 19 ; Navneet Singh, MD, DM 20 ; David R. Spigel,MD 21 ; Janis O. Stabler 22 ; Joan Tashbar 23 ;and Gregory Masters,MD 24 abstract PURPOSE The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) without driver

2020 Cancer Care Ontario

3. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer Osimertinib for untreated EGFR mutation-positive non- small-cell lung cancer T echnology appraisal guidance Published: 22 January 2020 www.nice.org.uk/guidance/ta621 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 19Contents Contents 1 Recommendations 4 2 Information about osimertinib 5 Marketing authorisation

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

4. Lung Cancer Surveillance After Definitive Curative-Intent Therapy

Lung Cancer Surveillance After Definitive Curative-Intent Therapy Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02748 Journal of Clinical Oncology - published online before print December 12, 2019 PMID: Lung Cancer Surveillance After Definitive Curative-Intent Therapy (...) /Cornell University, New York, NY Abstract Section: PURPOSE To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non–small-cell lung cancer (NSCLC) and SCLC. METHODS ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology, primary care, and advocacy experts to conduct a literature search, which included

2020 American Society of Clinical Oncology Guidelines

5. Prevalence of incidental findings of low dose computed tomography (LDCT) scans in lung cancer screening

Prevalence of incidental findings of low dose computed tomography (LDCT) scans in lung cancer screening Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

6. Outdoor particulate matter exposure and lung cancer risk: a systematic review and meta-analysis based on individual outcome

Outdoor particulate matter exposure and lung cancer risk: a systematic review and meta-analysis based on individual outcome Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

7. Is thrombocytosis associated with a particular subtype of lung cancer? A systematic review and meta-analysis.

Is thrombocytosis associated with a particular subtype of lung cancer? A systematic review and meta-analysis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

8. Lung cancer with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis

Lung cancer with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2020 PROSPERO

9. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study Patient-reported Outcomes With Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small-Cell Lung Cancer (PACIFIC): A Randomised, Controlled, Phase 3 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed (...) to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Lancet Oncol Actions , 20 (12), 1670-1680 Dec 2019 Patient-reported Outcomes With Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small-Cell Lung Cancer (PACIFIC): A Randomised

2020 EvidenceUpdates

10. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several (...) than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 38 (2), 115-123 2020 Jan 10 Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

11. Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) Atezolizumab with carboplatin and nab- paclitaxel for untreated advanced non-squamous non- small-cell lung cancer (terminated appraisal) T echnology appraisal guidance Published: 15 January 2020 www.nice.org.uk/guidance/ta618 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents (...) Contents Advice 3 Information 3 Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small- cell lung cancer (terminated appraisal) (TA618) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make a recommendation about the use in the NHS of atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Comparison of immune-related adverse events (irAEs) of combination of PD-(L)1 inhibitors and chemotherapy versus PD-(L)1 inhibitors for non-small cell lung cancer: a meta-analysis of randomised controlled trials

Comparison of immune-related adverse events (irAEs) of combination of PD-(L)1 inhibitors and chemotherapy versus PD-(L)1 inhibitors for non-small cell lung cancer: a meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD

2020 PROSPERO

13. A systematic review of the economic burden of lung cancer

A systematic review of the economic burden of lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2020 PROSPERO

14. Hand-held Fan Airflow Stimulation Relieves Dyspnea in Lung Cancer Patients. Full Text available with Trip Pro

Hand-held Fan Airflow Stimulation Relieves Dyspnea in Lung Cancer Patients. The main symptom of lung cancer is dyspnea which can lead to depression, anxiety, limited independent activities, and decreased quality of life. The purpose of this study was to identify the effect of airflow stimulation from a hand-held fan as nonpharmacological palliative intervention on dyspnea in patients with lung cancer.This study used open, randomized, controlled, crossover trial design involved 21 participants (...) . Diaphragmatic breathing technique was used in control arm.Wilcoxon test result showed that airflow stimulation significantly influenced dyspnea scale (P = 0.003) and respiratory rate (RR) (P = 0.008). Combination of airflow stimulation and diaphragmatic breathing can lower both dyspnea scale and RR significantly (P < 0.0001).This combination can be applied on nonhypoxemic dyspneic lung cancer patients.

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

15. Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group Full Text available with Trip Pro

Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group Low-dose computed tomography (LDCT) screening detects early-stage lung cancer and reduces mortality. We proposed a sequential approach targeted to a high-risk group as a potentially efficient screening strategy.LungSEARCH was a national multicentre randomised trial (...) . Current/ex-smokers with mild/moderate chronic obstructive pulmonary disease (COPD) were allocated (1:1) to have 5 years surveillance or not. Screened participants provided annual sputum samples for cytology and cytometry, and if abnormal were offered annual LDCT and autofluorescence bronchoscopy (AFB). Those with normal sputum provided annual samples. The primary end-point was the percentage of lung cancers diagnosed at stage I/II (nonsmall cell) or limited disease (small cell).1568 participants were

2019 EvidenceUpdates

16. Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lung cancer (NSCLC) Published 09 December 2019 1 Statement of advice SMC2254 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 8 November 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation atezolizumab (Tecentriq®) is not recommended for use within NHSScotland. Indication under review: In combination with nab-paclitaxel and carboplatin for the first (...) -line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium

2019 Scottish Medicines Consortium

17. Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma

Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

18. Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Dacomitinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A19-39 Dacomitinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-39 Version 1.0 Dacomitinib (non-small cell lung cancer) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dacomitinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

19. Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance

Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance Guideline Endorsement 7-13-2 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National (...) Institute for Health and Care Excellence Guidance M. Taremi, E.T. Vella, S. Cheng, P.M. Ellis, R. Goffin, A. Louie, R. MacRae, Y.C. Ung, and the Lung Cancer Disease Site Group Report Date: November 11, 2019 This document describes the CCO-Lung Cancer Disease Site Group endorsement of the recommendations for prophylactic cranial irradiation and consolidative radiation for patients with small cell lung cancer from © NICE [2019] Lung cancer: diagnosis and management. The original publication is available

2019 Cancer Care Ontario

20. Atezolizumab (Tecentriq) - non-squamous non-small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) - non-squamous non-small cell lung cancer (NSCLC) 1 Published 11 November 2019 1 SMC2208 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under (...) the end of life medicine process: atezolizumab (Tecentriq ® ) is not recommended for use within NHSScotland. Indication under review: In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin

2019 Scottish Medicines Consortium